Sphera Funds Management Ltd. Sage Therapeutics, Inc. Transaction History

Sphera Funds Management Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$40.65 - $59.54 $1.1 Million - $1.61 Million	-27,000 Reduced 17.42%	128,000 $6.02 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $46.57 $5.78 Million - $7.22 Million	155,000 New	155,000 $6.5 Million
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $604,340 - $827,685	-8,554 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$58.41 - $89.06 $499,639 - $761,819	8,554 New	8,554 $740,000
Q1 2019 May 15, 2019	SELL	$89.33 - $163.65 $9.25 Million - $16.9 Million	-103,500 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$81.94 - $139.71 $3.56 Million - $6.08 Million	43,500 Added 72.5%	103,500 $9.91 Million
Q3 2018 Nov 14, 2018	BUY	$138.11 - $169.04 $8.29 Million - $10.1 Million	60,000 New	60,000 $8.48 Million
Q1 2018 May 10, 2018	SELL	$152.15 - $192.33 $4.56 Million - $5.77 Million	-30,000 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$60.72 - $167.34 $1.45 Million - $4 Million	23,882 Added 390.36%	30,000 $4.94 Million
Q3 2017 Nov 09, 2017	BUY	$61.4 - $88.52 $375,645 - $541,565	6,118	6,118 $381,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.